Online inquiry

IVTScrip™ mRNA-Anti-EGFR, 1-26/3-67(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ157MR)

This product GTTS-WQ157MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, 1-26/3-67(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ157MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ488MR IVTScrip™ mRNA-Anti-SELP, 42-89-glycoprotein(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 42-89-glycoprotein
GTTS-WQ6977MR IVTScrip™ mRNA-Anti-pagA, ETI-204(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ETI-204
GTTS-WQ3228MR IVTScrip™ mRNA-Anti-FCGRT, ARGX-113(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ARGX-113
GTTS-WQ4279MR IVTScrip™ mRNA-Anti-LINGO1, BIIB-033(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BIIB-033
GTTS-WQ12608MR IVTScrip™ mRNA-Anti-F11, NVS250519(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA NVS250519
GTTS-WQ2916MR IVTScrip™ mRNA-Anti-ERBB3, AMG888(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG888
GTTS-WQ15770MR IVTScrip™ mRNA-Anti-CA9, WX-G250(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA WX-G250
GTTS-WQ10763MR IVTScrip™ mRNA-Anti-FGFR4, M-70(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA M-70
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW